In an in vivo glioma-bearing mice model the intravenous administration of the nanoparticles increased the median survival time and enhanced the BBB-crossing and glioma-targeting efficacy of ING4, decreasing the tumor volume [183]. The gene discussed is ING4; the disease is central nervous system cancer.